Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Multiple claims about adapalene’s regulatory/OTC availability in European countries are not supported by the provided FDA prescribing information excerpts, and the pregnancy-related counseling is partially supported with extra, unsupported phrasing. Some application/treatment and local reaction avoidance statements are generally consistent with the label.
Category Scores
Accurate Statements
Adapalene is usually used at night.
Label Dosage: Apply a thin film once daily in the evening (2); Patient counseling: apply once daily in the evening (17).
Adapalene can cause skin irritation, especially at first.
Warnings: local cutaneous reactions reported and most likely in first four weeks (5.3); Clinical trial irritation decreased with continued use (6.1).
Adapalene should be avoided in the eyes.
Dosage: Avoid application to areas around eyes (2); Patient counseling: Avoid contact with eyes (17).
Adapalene should be avoided on broken skin.
Warnings: Avoid application to cuts/abrasions (5.3); Patient counseling: do not apply to cuts, abrasions (17).
Unsupported Statements
Adapalene is a prescription-strength retinoid in many European countries.
Foreign-country regulatory/market-access statement is absent from the provided label excerpts.
Adapalene is not generally sold as an over-the-counter (OTC) acne treatment across the European Union.
EU-wide OTC availability statement is absent from the provided label excerpts.
OTC access for adapalene depends on each specific country's drug classification rules.
Country-by-country classification mechanism is absent from the provided label excerpts.
The EU does not operate a single, uniform OTC/pharmacy-only rule for medicines like adapalene.
EU policy generalization is absent from the provided label excerpts.
Some EU countries allow certain retinoid products only through pharmacies and/or with a prescription.
Jurisdiction-specific access restriction is absent from the provided label excerpts.
In practice, the current status of adapalene OTC availability depends on the specific country's regulations or the product's legal status on the package or within local pharmacy systems.
Practical OTC availability dependence on package/local pharmacy systems is absent from the provided label excerpts.
OTC availability (where it exists) often hinges on concentration.
Concentration-driven OTC availability statement is absent from the provided label excerpts.
Higher-strength adapalene acne gels are more likely to be prescription medicines.
No label support correlating strength with prescription status.
Lower-dose or alternative formulations of adapalene may be treated differently by regulators.
No label support for regulator treatment differences across formulations/jurisdictions.
People who are pregnant or planning pregnancy should discuss options with a clinician before using retinoids.
This specific counseling instruction for 'planning pregnancy' and clinician discussion is absent from the provided label excerpts.
Contradictions
Important Omissions
If not noticed after 12 weeks of treatment, therapy should be re-evaluated (relevant to administration/duration).
Importance:
Moderate
Contraindication: hypersensitivity to adapalene or excipients (not evaluated in the response, but relevant to safety).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported statements about foreign OTC access could mislead about how the product is obtained; pregnancy-related counseling includes unsupported directives beyond label phrasing. Remaining local-use and irritation/avoidance statements are largely consistent with the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Multiple regulatory/OTC availability claims for Europe are absent from the provided FDA label excerpts; pregnancy counseling contains unsupported language.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label sections (e.g., dosing/applying once daily in the evening; avoid eyes/angles of nose/mucous membranes; avoid cuts/abrasions/eczema/sunburned skin; local irritation timing and mitigation). Remove or qualify all Europe/OTC access assertions not found in the label excerpts.